Canakinumab in Patients With Active Hyper-IgD Syndrome
NCT01303380
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
9
Enrollment
INDUSTRY
Sponsor class
Conditions
Mevalonate Kinase Deficiency
Interventions
DRUG:
Canakinumab
Sponsor
Novartis Pharmaceuticals